ENDOTHELIAL DYSFUNCTION AND NEUROHUMORAL REGULATION OF BLOOD PRESSURE IN PATIENTS WITH SYSTEMIC SCLEROSIS
https://doi.org/10.14412/1995-4484-2019-445-451
Abstract
Objective: to investigate the effect of endothelial dysfunction, catecholamines, and renin on the diurnal blood pressure (BP) profile in patients with systemic sclerosis (SS).
Subjects and methods. Twenty-five patients with SS underwent determination of the blood count of desquamated endotheliocytes by the method described by J. Hladovec (1978), the plasma levels of endothelin-1 (ET-1), adrenaline, norepinephrine, and renin by enzyme immunoassay. All the patients underwent 24-hour BP monitoring with calculating the time index, daily index, the magnitude and rate of a morning rise in BP, as well as its daily variability.
Results and discussion. Hypertension was detected in 8 (32%) patients with SS. All the patients with SS showed signs of endothelial dysfunction, as evidenced by considerable differences in endothelial activation measures compared with the control group: the mean level of ET-1 was 5.8±2.3 and 0.48±0.21 fmol/ml (p<0.05); the number of desquamated endotheliocytes was 4.50 [3.00; 7.00] and 2.10 [1.00; 3.20] • 104/l, respectively (p<0.05). The levels of adrenaline and norepinephrine in SS were significantly higher than those in the control. There were positive correlations between endothelial dysfunction and the degree of an increase in BP. Endothelial dysfunction was found to have a negative impact on the diurnal BP profile in the presence of pathological types of night-peaker and non-dipper.
Conclusion. Two mechanisms, such as endothelial dysfunction and sympathoadrenal activation, are responsible for the pathogenesis of clinical symptoms of SS, including hypertension.
About the Authors
N. P. Shilkina
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Yaroslavl
Russian Federation
Yaroslavl
I. E. Yunonin
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Yaroslavl
Russian Federation
Yaroslavl
S. A. Stolyarova
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Yaroslavl
Russian Federation
Yaroslavl
A. A. Vinogradov
Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Yaroslavl
Russian Federation
Yaroslavl
References
1. Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford). 2005;44:1212-6. doi: 10.1093/rheumatology/keh671
2. Koneva OA, Ovsyannikova OB, Starovoitova MN, et al. Aassessment of thesensitivity of new criteria for systemic sclerosis in Russian patient population. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015; 53(4):361-6 (In Russ.). doi: 10.14412/1995-4484-2015-361-366
3. Guseva NG. Systemic sclerosis: early diagnosis and prognosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(1):39-45 (In Russ.).
4. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria For Systemic Sclerosis: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424
5. Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford). 2005;44:1212-6. doi: 10.1093/rheumatology/keh671
6. Ananyeva LP. New classification criteria for scleroderma systematica (a lecture). Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):539-44 (In Russ.). doi: 10.14412/1995-4484-2013-1546
7. Koneva OA, Ovsyannikova OB, Starovoitova MN, et al. Aassessment of thesensitivity of new criteria for systemic sclerosis in Russian patient population. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015; 53(4):361-6 (In Russ.). doi: 10.14412/1995-4484-2015-361-366
8. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria For Systemic Sclerosis: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424
9. Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res. 2017 Aug;65(4):790-7. doi: 10.1007/s12026-017-8926-y
10. Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford). 2005;44:1212-6. doi: 10.1093/rheumatology/keh671
11. Ananyeva LP, Aleksandrova EN. Autoantibodies in scleroderma systematica: Spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.). doi: 10.14412/1995-4484-2016-86-99
12. Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res. 2017 Aug;65(4):790-7. doi: 10.1007/s12026-017-8926-y
13. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria For Systemic Sclerosis: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424
14. Ananyeva LP, Aleksandrova EN. Autoantibodies in scleroderma systematica: Spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.). doi: 10.14412/1995-4484-2016-86-99
15. Butusova SV, Shilkina NP. Early diagnosis of endothelial lesions in patients with rheumatoid arthritis. Vrach. 2014;(5):67-9 (In Russ.).
16. Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis-current concept and emerging treatments. Immunol Res. 2017 Aug;65(4):790-7. doi: 10.1007/s12026-017-8926-y
17. Butusova SV, Shilkina NP. Early diagnosis of endothelial lesions in patients with rheumatoid arthritis. Vrach. 2014;(5):67-9 (In Russ.).
18. Klimek E, Skalska A. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:ID681635. doi: 10.1155/2014/681635
19. Ananyeva LP, Aleksandrova EN. Autoantibodies in scleroderma systematica: Spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.). doi: 10.14412/1995-4484-2016-86-99
20. Routledge FS, Hinderliter AL. Endothelial function in postmenopausal women with nighttime systolic hypertension. Menopause. 2015;8:857-63. doi: 10.1097/GME.0000000000000405
21. Klimek E, Skalska A. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:ID681635. doi: 10.1155/2014/681635
22. Butusova SV, Shilkina NP. Early diagnosis of endothelial lesions in patients with rheumatoid arthritis. Vrach. 2014;(5):67-9 (In Russ.).
23. Routledge FS, Hinderliter AL. Endothelial function in postmenopausal women with nighttime systolic hypertension. Menopause. 2015;8:857-63. doi: 10.1097/GME.0000000000000405
24. Small HY, Migliatino S, Czesnikiewicz-Guzik M, Guzik TJ. Hypertension: Focus on autoimmunity and oxidative stress. Free Radic Biol Med. 2018 Sep;125:104-15. doi: 10.1016/j.freeradbiomed.2018.05.085
25. Klimek E, Skalska A. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:ID681635. doi: 10.1155/2014/681635
26. Small HY, Migliatino S, Czesnikiewicz-Guzik M, Guzik TJ. Hypertension: Focus on autoimmunity and oxidative stress. Free Radic Biol Med. 2018 Sep;125:104-15. doi: 10.1016/j.freeradbiomed.2018.05.085
27. Weber T, Wassertheurer S. Relationship between 24-hour ambulatory central blood pressure and left ventricular mass – a prospective multicenter study. J Hypertens. 2016;34 Suppl. 1):Abstract Book: 210-11.
28. Routledge FS, Hinderliter AL. Endothelial function in postmenopausal women with nighttime systolic hypertension. Menopause. 2015;8:857-63. doi: 10.1097/GME.0000000000000405
29. Rebrova NV, Anisimova EA, Sarkisova OL, et al. Cerebrovascular reactivity in patients with rheumatoid arthritis concurrent with and without hypertension. Terapevticheskiy arkhiv. 2015;87(4):24-9 (In Russ.). doi: 10.17116/terarkh201587424-29
30. Weber T, Wassertheurer S. Relationship between 24-hour ambulatory central blood pressure and left ventricular mass – a prospective multicenter study. J Hypertens. 2016;34 Suppl. 1):Abstract Book: 210-11.
31. Small HY, Migliatino S, Czesnikiewicz-Guzik M, Guzik TJ. Hypertension: Focus on autoimmunity and oxidative stress. Free Radic Biol Med. 2018 Sep;125:104-15. doi: 10.1016/j.freeradbiomed.2018.05.085
32. Rebrova NV, Anisimova EA, Sarkisova OL, et al. Cerebrovascular reactivity in patients with rheumatoid arthritis concurrent with and without hypertension. Terapevticheskiy arkhiv. 2015;87(4):24-9 (In Russ.). doi: 10.17116/terarkh201587424-29
33. Chen CT, Li Y. Association between ambulatory systolic blood pressure during the day and asymptomatic intracranial arterial stenosis. J Hypertens. 2014;63:61-7. doi: 10.1161/HYPERTENSIONAHA.113.01838
34. Weber T, Wassertheurer S. Relationship between 24-hour ambulatory central blood pressure and left ventricular mass – a prospective multicenter study. J Hypertens. 2016;34 Suppl. 1):Abstract Book: 210-11.
35. Cheremukhina EO, Anan'eva LP, Novikova DS, Alekperov RT. Heart rate variability in systemic scleroderma. Klinicheskaya Farmakologiya i Terapiya. 2015;24(1):61-5 (In Russ.).
36. Chen CT, Li Y. Association between ambulatory systolic blood pressure during the day and asymptomatic intracranial arterial stenosis. J Hypertens. 2014;63:61-7. doi: 10.1161/HYPERTENSIONAHA.113.01838
37. Rebrova NV, Anisimova EA, Sarkisova OL, et al. Cerebrovascular reactivity in patients with rheumatoid arthritis concurrent with and without hypertension. Terapevticheskiy arkhiv. 2015;87(4):24-9 (In Russ.). doi: 10.17116/terarkh201587424-29
38. Khusainova DK, Tregulov YuE, Salikhov IG, et al. Endothelial dysfunction and arterial hypertension in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2006;44(3):27-32 (In Russ.).
39. Cheremukhina EO, Anan'eva LP, Novikova DS, Alekperov RT. Heart rate variability in systemic scleroderma. Klinicheskaya Farmakologiya i Terapiya. 2015;24(1):61-5 (In Russ.).
40. Chen CT, Li Y. Association between ambulatory systolic blood pressure during the day and asymptomatic intracranial arterial stenosis. J Hypertens. 2014;63:61-7. doi: 10.1161/HYPERTENSIONAHA.113.01838
41. Starovoitova MN, Desinova OV. Therapy for digital ulcers in patients with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):777-81 (In Russ.). doi: 10.14412/1995-4484-2018-777-781
42. Khusainova DK, Tregulov YuE, Salikhov IG, et al. Endothelial dysfunction and arterial hypertension in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2006;44(3):27-32 (In Russ.).
43. Cheremukhina EO, Anan'eva LP, Novikova DS, Alekperov RT. Heart rate variability in systemic scleroderma. Klinicheskaya Farmakologiya i Terapiya. 2015;24(1):61-5 (In Russ.).
44. Herrick AL. Management of Raynaud’s phenomenon and digital ischemia. Curr Rhеumatol Rep. 2013;15:303. doi: 10.1007/s11926-012-0303-1
45. Starovoitova MN, Desinova OV. Therapy for digital ulcers in patients with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):777-81 (In Russ.). doi: 10.14412/1995-4484-2018-777-781
46. Khusainova DK, Tregulov YuE, Salikhov IG, et al. Endothelial dysfunction and arterial hypertension in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2006;44(3):27-32 (In Russ.).
47. Herrick AL. Management of Raynaud’s phenomenon and digital ischemia. Curr Rhеumatol Rep. 2013;15:303. doi: 10.1007/s11926-012-0303-1
48. Silva I, Teixeira A, Oliveira J, et al. Endothelial dysfunction, microvascular damadge and ischemic peripheral vasculopathy in systemic sclerosis. Clin Hemorheol Microcirc. 2017;66 (2):117-30. doi: 10.3233/CH-150044
49. Starovoitova MN, Desinova OV. Therapy for digital ulcers in patients with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):777-81 (In Russ.). doi: 10.14412/1995-4484-2018-777-781
50. Silva I, Teixeira A, Oliveira J, et al. Endothelial dysfunction, microvascular damadge and ischemic peripheral vasculopathy in systemic sclerosis. Clin Hemorheol Microcirc. 2017;66 (2):117-30. doi: 10.3233/CH-150044
51. Jung C, Drummer K, Oelzner P, et al. The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud's phenomenon as detected by functional imaging. Clin Hemorheol Microcirc. 2015;61(3):549-57. doi: 10.3233/CH-151956
52. Herrick AL. Management of Raynaud’s phenomenon and digital ischemia. Curr Rhеumatol Rep. 2013;15:303. doi: 10.1007/s11926-012-0303-1
53. Alekperov RT, Ananyeva LP, Cherkasova MV. Clinical associations of vascular endothelial growth factor and its type 2 receptor in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):569-73 (In Russ.). doi: 10.14412/1995-4484-2018-569-573
54. Jung C, Drummer K, Oelzner P, et al. The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud's phenomenon as detected by functional imaging. Clin Hemorheol Microcirc. 2015;61(3):549-57. doi: 10.3233/CH-151956
55. Silva I, Teixeira A, Oliveira J, et al. Endothelial dysfunction, microvascular damadge and ischemic peripheral vasculopathy in systemic sclerosis. Clin Hemorheol Microcirc. 2017;66 (2):117-30. doi: 10.3233/CH-150044
56. Alekperov RT, Ananyeva LP, Cherkasova MV. Clinical associations of vascular endothelial growth factor and its type 2 receptor in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):569-73 (In Russ.). doi: 10.14412/1995-4484-2018-569-573
57. Rebrov AP, Patrikeeva DA, Zakharova NB, et al. Diagnostic value of determining angiogenesis factors and cytokine composition indicators in serum and urine in patients with systemic scleroderma. Terapevticheskii Arkhiv. 2014;(5):19-25 (In Russ.).
58. Jung C, Drummer K, Oelzner P, et al. The association between endothelial microparticles and inflammation in patients with systemic sclerosis and Raynaud's phenomenon as detected by functional imaging. Clin Hemorheol Microcirc. 2015;61(3):549-57. doi: 10.3233/CH-151956
59. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmune Rev. 2011;10(10):641-6. doi: 10.1016/j.autrev.2011.04.019
60. Rebrov AP, Patrikeeva DA, Zakharova NB, et al. Diagnostic value of determining angiogenesis factors and cytokine composition indicators in serum and urine in patients with systemic scleroderma. Terapevticheskii Arkhiv. 2014;(5):19-25 (In Russ.).
61. Alekperov RT, Ananyeva LP, Cherkasova MV. Clinical associations of vascular endothelial growth factor and its type 2 receptor in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):569-73 (In Russ.). doi: 10.14412/1995-4484-2018-569-573
62. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. doi: 10.1172%2FJCI31139
63. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmune Rev. 2011;10(10):641-6. doi: 10.1016/j.autrev.2011.04.019
64. Rebrov AP, Patrikeeva DA, Zakharova NB, et al. Diagnostic value of determining angiogenesis factors and cytokine composition indicators in serum and urine in patients with systemic scleroderma. Terapevticheskii Arkhiv. 2014;(5):19-25 (In Russ.).
65. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. doi: 10.1172%2FJCI31139
66. Manetti M, Romano E, Rosa I, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017 May;76(5):924-34. doi: 10.1136/annrheumdis-2016-210229. Epub 2017 Jan 6.
67. Liakouli V, Cipriani P, Marrelli A, et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmune Rev. 2011;10(10):641-6. doi: 10.1016/j.autrev.2011.04.019
68. Romano E, Rosa I, Fioretto BS, et al. A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and nervous systems. Clin Exp Rheumatol. 2019;11 [Epub ahead of print].
69. Manetti M, Romano E, Rosa I, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017 May;76(5):924-34. doi: 10.1136/annrheumdis-2016-210229. Epub 2017 Jan 6.
70. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. doi: 10.1172%2FJCI31139
71. Romano E, Rosa I, Fioretto BS, et al. A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and nervous systems. Clin Exp Rheumatol. 2019;11 [Epub ahead of print].
72. Dessein PH, Joffe BI, Metz RM, et al. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Arthritis Rheum. 1994 Jan;37(1):67-74.
73. Manetti M, Romano E, Rosa I, et al. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Ann Rheum Dis. 2017 May;76(5):924-34. doi: 10.1136/annrheumdis-2016-210229. Epub 2017 Jan 6.
74. Dessein PH, Joffe BI, Metz RM, et al. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Arthritis Rheum. 1994 Jan;37(1):67-74.
75. Shilkina NP, Savina ZhE, Yunonin IE. Hyperrenin forms of arterial hypertension in systemic lupus erythematosus and their correction. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2 Suppl.1):139-40 (In Russ.).
76. Romano E, Rosa I, Fioretto BS, et al. A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and nervous systems. Clin Exp Rheumatol. 2019;11 [Epub ahead of print].
77. Woodworth TG, Suliman YA, Li W, et al. Sleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678-91. doi: 10.1038/nrnerh.2016.124
78. Shilkina NP, Savina ZhE, Yunonin IE. Hyperrenin forms of arterial hypertension in systemic lupus erythematosus and their correction. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2 Suppl.1):139-40 (In Russ.).
79. Dessein PH, Joffe BI, Metz RM, et al. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Arthritis Rheum. 1994 Jan;37(1):67-74.
80. Woodworth TG, Suliman YA, Li W, et al. Sleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678-91. doi: 10.1038/nrnerh.2016.124
81. Si Ahmed-Bouali D, Bouali F, Haddoum F, et al. Hypertension in scleroderma: A vital emergency. Ann Cardiol Angeiol. 2015;64(3):192-8. doi: 10.1016/ancard.2015.04.009
82. Shilkina NP, Savina ZhE, Yunonin IE. Hyperrenin forms of arterial hypertension in systemic lupus erythematosus and their correction. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2 Suppl.1):139-40 (In Russ.).
83. Si Ahmed-Bouali D, Bouali F, Haddoum F, et al. Hypertension in scleroderma: A vital emergency. Ann Cardiol Angeiol. 2015;64(3):192-8. doi: 10.1016/ancard.2015.04.009
84. Kowal-Bielecka O, Fransen J, Avouac J, et al. EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;0:1-12. doi: 10.1136/annrheumdis-2016-209909
85. Woodworth TG, Suliman YA, Li W, et al. Sleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016 Nov;12(11):678-91. doi: 10.1038/nrnerh.2016.124
86. Kowal-Bielecka O, Fransen J, Avouac J, et al. EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;0:1-12. doi: 10.1136/annrheumdis-2016-209909
87. Korn JH, Mayes M, Matucci-Cerenic M, for the RAPIDS-1 study group. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rhеum. 2004;50:3985-93. doi: 10.1002/art.20676
88. Si Ahmed-Bouali D, Bouali F, Haddoum F, et al. Hypertension in scleroderma: A vital emergency. Ann Cardiol Angeiol. 2015;64(3):192-8. doi: 10.1016/ancard.2015.04.009
89. Korn JH, Mayes M, Matucci-Cerenic M, for the RAPIDS-1 study group. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rhеum. 2004;50:3985-93. doi: 10.1002/art.20676
90. Klyaus NA, Simakova MA, Maslyansky AL, Moiseeva OM. Search for clinical predictors of pulmonary hypertension in patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):586-90 (In Russ.). doi: 10.14412/1995-4484-2018-586-590
91. Kowal-Bielecka O, Fransen J, Avouac J, et al. EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;0:1-12. doi: 10.1136/annrheumdis-2016-209909
92. Klyaus NA, Simakova MA, Maslyansky AL, Moiseeva OM. Search for clinical predictors of pulmonary hypertension in patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):586-90 (In Russ.). doi: 10.14412/1995-4484-2018-586-590
93. Corallo C, Cutolo M, Kahaleh B, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228. doi: 10.1186/s13075-016-1122-y
94. Korn JH, Mayes M, Matucci-Cerenic M, for the RAPIDS-1 study group. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rhеum. 2004;50:3985-93. doi: 10.1002/art.20676
95. Corallo C, Cutolo M, Kahaleh B, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228. doi: 10.1186/s13075-016-1122-y
96. Volkov AV, Martynyuk TV, Yudkina NN, et al. The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(6):22-7 (In Russ.). doi: 10.14412/1995-4484-2011-515
97. Klyaus NA, Simakova MA, Maslyansky AL, Moiseeva OM. Search for clinical predictors of pulmonary hypertension in patients with systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):586-90 (In Russ.). doi: 10.14412/1995-4484-2018-586-590
98. Volkov AV, Martynyuk TV, Yudkina NN, et al. The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(6):22-7 (In Russ.). doi: 10.14412/1995-4484-2011-515
99. Nevskaya TA, Anan'eva LP, Bykovskaya SYu, et al. Angiogenesis disorders and cellular methods for their correction in systemic scleroderma. In: V s"ezd revmatologov Rossii: Sb. mat. s"ezda (tezisy) [V congress of rheumatologists of Russia: Collection of materials of the congress (theses)]. Moscow; 2009 (In Russ.).
100. Corallo C, Cutolo M, Kahaleh B, et al. Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. Arthritis Res Ther. 2016 Oct 6;18(1):228. doi: 10.1186/s13075-016-1122-y
101. Nevskaya TA, Anan'eva LP, Bykovskaya SYu, et al. Angiogenesis disorders and cellular methods for their correction in systemic scleroderma. In: V s"ezd revmatologov Rossii: Sb. mat. s"ezda (tezisy) [V congress of rheumatologists of Russia: Collection of materials of the congress (theses)]. Moscow; 2009 (In Russ.).
102. Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and metaanalysis of the literature. Arthritis Res Ther. 2019;21:86 doi: 10.1186/s13075-019-1867-1
103. Volkov AV, Martynyuk TV, Yudkina NN, et al. The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(6):22-7 (In Russ.). doi: 10.14412/1995-4484-2011-515
104. Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and metaanalysis of the literature. Arthritis Res Ther. 2019;21:86 doi: 10.1186/s13075-019-1867-1
105. Nevskaya TA, Anan'eva LP, Bykovskaya SYu, et al. Angiogenesis disorders and cellular methods for their correction in systemic scleroderma. In: V s"ezd revmatologov Rossii: Sb. mat. s"ezda (tezisy) [V congress of rheumatologists of Russia: Collection of materials of the congress (theses)]. Moscow; 2009 (In Russ.).
106. Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and metaanalysis of the literature. Arthritis Res Ther. 2019;21:86 doi: 10.1186/s13075-019-1867-1
Review
For citations:
Shilkina N.P., Yunonin I.E., Stolyarova S.A., Vinogradov A.A. ENDOTHELIAL DYSFUNCTION AND NEUROHUMORAL REGULATION OF BLOOD PRESSURE IN PATIENTS WITH SYSTEMIC SCLEROSIS. Rheumatology Science and Practice. 2019;57(4):445-451. (In Russ.) https://doi.org/10.14412/1995-4484-2019-445-451
Views:
696
Email this article 